Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab. Fujita R, Aratake Y, Nakata K, Fujii C, et al. Intern Med 2023;62:3317-3320.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fujita R, Aratake Y, Nakata K, Fujii C, et al. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab. Intern Med 2023;62:3317-3320.
PMID: 37032080